Development of an optimized multi-biomarker panel for the detection of lung cancer based on principal component analysis and artificial neural network modeling

被引:29
作者
Miguel Flores-Fernandez, Jose [1 ]
Herrera-Lopez, Enrique J. [1 ]
Sanchez-Llamas, Francisco [2 ]
Rojas-Calvillo, Antonio [3 ]
Anel Cabrera-Galeana, Paula [3 ]
Leal-Pacheco, Gisela [1 ]
Guadalupe Gonzalez-Palomar, Maria [1 ]
Femat, R. [4 ]
Martinez-Velazquez, Moises [1 ]
机构
[1] Ctr Invest & Asistencia Tecnol & Diseno Estado Ja, Guadalajara 44270, Jalisco, Mexico
[2] OPD Antigua Hosp Civil Guadalajara Fray Antonio A, Serv Fisiol Pulmonar & Inhaloterapia, Guadalajara 44280, Jalisco, Mexico
[3] Ctr Oncol Estatal ISSEMYM, Toluca, Estado De Mexic, Mexico
[4] IPICyT, Div Matemat Aplicadas, San Luis Potosi 78216, Mexico
关键词
Biomarkers; Artificial neural network; Principal component analysis; Diagnosis; Lung cancer; COMPUTED-TOMOGRAPHY; TUMOR-ANTIGEN; IDENTIFICATION; SENSITIVITY; DIAGNOSIS; MORTALITY;
D O I
10.1016/j.eswa.2012.03.008
中图分类号
TP18 [人工智能理论];
学科分类号
081104 ; 0812 ; 0835 ; 1405 ;
摘要
Lung cancer is a public health priority worldwide due to the high mortality rate and the costs involved. Early detection of lung cancer is important for increasing the survival rate, however, frequently its diagnosis is not made opportunely, since detection methods are not sufficiently sensitive and specific. In recent years serum biomarkers have been proposed as a method that might enhance diagnostic capabilities and complement imaging studies. However, when used alone they show low sensitivity and specificity because lung cancer is a heterogeneous disease. Recent reports have shown that simultaneous analysis of biomarkers has the potential to separate lung cancer patients from control subjects. However, it has become clear that a universal biomarker panel does not exist, and optimized panels need to be developed and validated in each population before their application in a clinical setting. In this study, we selected 14 biomarkers from literature, whose diagnostic or prognostic value had been previously demonstrated for lung cancer, and evaluated them in sera from 63 patients with lung cancer and 87 non-cancer controls (58 Chronic Obstructive Pulmonary Disease (COPD) patients and 29 current smokers). Principal component analysis and artificial neural network modeling allowed us to find a reduced biomarker panel composed of Cyfra 21.1, CEA, CA125 and CRP. This panel was able to correctly classify 135 out of 150 subjects, showing a correct classification rate for lung cancer patients of 88.9%, 93.3% and 90% in training, validation and testing phases, respectively. Thus, sensitivity was increased 18.31% (sensitivity 94.5% at specificity 80%) with respect to the best single marker Cyfra 21.1. This optimized panel represents a potential tool for assisting lung cancer diagnosis, therefore it merits further consideration. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:10851 / 10856
页数:6
相关论文
共 34 条
[1]  
[Anonymous], 2010, INT J ENG SCI
[2]  
[Anonymous], NCCN CLIN PRACT GUID
[3]   Noninvasive detection of lung cancer by analysis of exhaled breath [J].
Bajtarevic, Amel ;
Ager, Clemens ;
Pienz, Martin ;
Klieber, Martin ;
Schwarz, Konrad ;
Ligor, Magdalena ;
Ligor, Tomasz ;
Filipiak, Wojciech ;
Denz, Hubert ;
Fiegl, Michael ;
Hilbe, Wolfgang ;
Weiss, Wolfgang ;
Lukas, Peter ;
Jamnig, Herbert ;
Hackl, Martin ;
Haidenberger, Alfred ;
Buszewski, Boguslaw ;
Miekisch, Wolfram ;
Schubert, Jochen ;
Amann, Anton .
BMC CANCER, 2009, 9 :348
[4]   Current concepts - Computed tomography - An increasing source of radiation exposure [J].
Brenner, David J. ;
Hall, Eric J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (22) :2277-2284
[5]   Cost of a 5-year lung cancer survivor: symptomatic tumour identification vs proactive computed tomography screening [J].
Castleberry, A. W. ;
Smith, D. ;
Anderson, C. ;
Rotter, A. J. ;
Grannis, F. W., Jr. .
BRITISH JOURNAL OF CANCER, 2009, 101 (06) :882-896
[6]   Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer [J].
Cho, William Chi-Shing .
BIOMEDICINE & PHARMACOTHERAPY, 2007, 61 (09) :515-519
[7]   Diagnostic values of SCC, CEA, Cyfra21-1 and NSE for lung cancer in patients with suspicious pulmonary masses A single center analysis [J].
Chu, Xiang-Yang ;
Hou, Xiao-Bin ;
Song, Wei-An ;
Xue, Zhi-Qiang ;
Wang, Bo ;
Zhang, Lian-Bin .
CANCER BIOLOGY & THERAPY, 2011, 11 (12) :995-1000
[8]   A multi-analyte serum test for the detection of non-small cell lung cancer [J].
Farlow, E. C. ;
Vercillo, M. S. ;
Coon, J. S. ;
Basu, S. ;
Kim, A. W. ;
Faber, L. P. ;
Warren, W. H. ;
Bonomi, P. ;
Liptay, M. J. ;
Borgia, J. A. .
BRITISH JOURNAL OF CANCER, 2010, 103 (08) :1221-1228
[9]   Development of a Multiplexed Tumor-Associated Autoantibody-Based Blood Test for the Detection of Non-Small Cell Lung Cancer [J].
Farlow, Erin C. ;
Patel, Kalpa ;
Basu, Sanjib ;
Lee, Bao-Shiang ;
Kim, Anthony W. ;
Coon, John S. ;
Faber, L. Penfield ;
Bonomi, Philip ;
Liptay, Michael J. ;
Borgia, Jeffrey A. .
CLINICAL CANCER RESEARCH, 2010, 16 (13) :3452-3462
[10]  
Feng F., 2011, J MED SYSTEMS